BioPorto Diagnostics A/S (CPH:BIOPOR), an in-vitro diagnostics company, announced on Tuesday that its board of directors will nominate Britt Meelby Jensen for election as a new board member at BioPorto's Annual General Meeting on 13 April 2018.
Since 2015, Jensen has been the CEO of Zealand Pharma A/S.
Jensen also has extensive global commercial and general management experiences from working in the life sciences area over the past 16 years at Novo Nordisk, Dako and Zealand Pharma.
BioPorto Diagnostics provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval